Resource Library

Beginning on 1 January 2014, French pharmacists are now legally permitted to substitute a biosimilar for the prescribed (reference) biological medicine as long as the prescribing physician has not marked the prescription as “non-substitutable.” According to the new law, substitution is allowed only when initiating a course of treatment, and if the biosimilar belongs to the same group as the prescribed product, known as a “similar biologic group.” The criteria for inclusion in a “similar biologic group” have yet to be defined by the French healthcare authority (ANSM).

This resource provides an overview of patent regulations in Switzerland, with a focus on enforcement proceedings, licensing, and ownership.

This article outlines what trade secret protection is, why you might choose it instead of a patent, and how to implement it.

This article summarises the legislative framework for the protection of personally<br />identifiable information (PII).

This article summarises the legislative framework for the protection of personally<br />identifiable information (PII).

Proposal for the reform of the data protection regime in the European Union

Patent enforcement proceedings in Greece.

Patent enforcement proceedings in Japan.

This article summarises the legislative framework for the protection of personally identifiable information (PII).

This article summarises the legislative framework for the protection of personally<br />identifiable information (PII).